Anika Therapeutics enters $75M senior revolving credit facility maturing 2026

Anika Therapeutics, Inc.

Third Amendment to Credit Agreement increases revolving line to $75M, expandable to $150M.
Maturity date extended to November 12, 2026; interest at BSBY + 0.25%-1.00%.
Amended agreement governs leverage and interest coverage covenants; first-priority lien on assets.
Bank of America serves as administrative agent; new lenders join the facility.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.